NCT05242744View on ClinicalTrials.gov

FTT PET/CT in Metastatic Prostate Cancer

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Prostate Cancer Metastatic
Interventions
DRUG

[18F]FluorThanatrace

Investigational radiopharmaceutical used with Positron Emission Tomography (PET/CT) imaging that may provide a non-invasive measurement of PARP-1 expression

Trial Locations (1)

19104

RECRUITING

University of Pennsylvania Hospital, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER